Pharma Stocks
-
Assessing Indivior Pharmaceuticals (INDV) Valuation After Strong Long Term Share Price Momentum
Indivior Pharmaceuticals stock after recent performance Indivior Pharmaceuticals (INDV) has drawn fresh attention after recent share performance, with the stock…
Read More » -
Mankind, other pharma stocks rally up to 7%; Nifty Pharma scales fresh peak. What lies ahead?
Shares of pharma companies rallied up to 7% on Wednesday as strong earnings, a weakening rupee, and other supportive factors…
Read More » -
FDA Approval Of Tessie Puts Orion’s Animal Health Potential In Focus
Orion Oyj (HLSE:ORNBV) has received FDA approval for its proprietary veterinary drug Tessie (tasipimidine) for use in the U.S. market.…
Read More » -
Chinese pharma player in focus after recent business u
Huadong Medicine Co Ltd has remained active with business and product updates, drawing attention to its role in China’s pharmaceutical…
Read More » -
Cosette Pharmaceuticals Appoints David Bell as Chief Commercial Officer (Brands)
Cosette Pharmaceuticals, Inc., a U.S.-based, branded specialty pharmaceutical company, announced today it has appointed David Bell as Chief Commercial Officer…
Read More » -
Aurobindo Pharma Sees Sharp Open Interest Surge Signallin…
Open Interest and Volume Dynamics The latest data reveals that Aurobindo Pharma’s open interest (OI) in derivatives rose sharply by…
Read More » -
Gland Pharma Limited Just Recorded A 8.8% EPS Beat: Here’s What Analysts Are Forecasting Next
A week ago, Gland Pharma Limited (NSE:GLAND) came out with a strong set of full-year numbers that could potentially lead…
Read More » -
Why Amphastar Pharmaceuticals (AMPH) Stock Is Trading Lower Today
What Happened? Shares of pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) fell 2.8% in the morning session after Wells Fargo downgraded the…
Read More » -
Royalty Pharma (RPRX) Benefits from Biotech Funding Gap with Rising Returns and Market Dominance
Latitude Investment Management, an investment management firm, released its fourth-quarter 2025 investor letter. A copy of the letter can be…
Read More » -
Q1 2026 beat, raised outlook and steady dividend attract fresh attenti
GSK plc has surprised the market with better-than-expected Q1 2026 results, a guidance increase and a maintained dividend, putting the…
Read More »